
## Xiaoxian Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2871520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Journal of the National Cancer Institute, 2008, 100, 672-679.	6.3	1,632
2	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13820-13825.	7.1	1,257
3	Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 161, 279-287.	2.5	335
4	An African-specific polymorphism in the <i>TP53</i> gene impairs p53 tumor suppressor function in a mouse model. Genes and Development, 2016, 30, 918-930.	5.9	277
5	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8838-8843.	7.1	99
6	A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Research, 2020, 22, 121.	5.0	89
7	ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ERâ^'/HER2+ Breast Cancer. Clinical Breast Cancer, 2019, 19, 236-245.	2.4	83
8	Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal of Clinical Pathology, 2016, 146, 496-502.	0.7	78
9	GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Human Pathology, 2016, 47, 26-31.	2.0	75
10	Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal of Clinical Pathology, 2016, 145, 871-878.	0.7	67
11	Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers. Human Pathology, 2017, 64, 7-12.	2.0	64
12	Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget, 2015, 6, 10487-10497.	1.8	58
13	Role of RPL39 in Metaplastic Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw292.	6.3	55
14	<i>Anti</i> -3- <sup>18</sup> F-FACBC ( <sup>18</sup> F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. Journal of Nuclear Medicine, 2016, 57, 1357-1363.	5.0	53
15	The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Modern Pathology, 2013, 26, 71-78.	5.5	44
16	New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives of Pathology and Laboratory Medicine, 2017, 141, 490-498.	2.5	40
17	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports, 2020, 10, 3009.	3.3	34

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL) Tj ETQq0 0 0 rgBT /Overback 10 Tf s 18

Xiaoxian Li

#	Article	IF	CITATIONS
19	Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Scientific Reports, 2017, 7, 42289.	3.3	30
20	High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Human Pathology, 2017, 66, 222-229.	2.0	30
21	Hormone Receptor-Positive Breast Cancer HasÂaÂWorse Prognosis in Male Than in FemaleÂPatients. Clinical Breast Cancer, 2017, 17, 356-366.	2.4	29
22	Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3587-3593.	1.2	25
23	Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ. Archives of Pathology and Laboratory Medicine, 2016, 140, 686-689.	2.5	24
24	Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database. Breast Cancer Research and Treatment, 2018, 171, 303-313.	2.5	24
25	Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer, 2020, 20, 19-24.	2.4	24
26	CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy. International Journal of Breast Cancer, 2018, 2018, 1-9.	1.2	22
27	Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast. American Journal of Clinical Pathology, 2017, 148, 167-172.	0.7	20
28	Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature. Gynecologic Oncology Reports, 2016, 15, 31-33.	0.6	18
29	Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Research and Treatment, 2020, 180, 321-329.	2.5	18
30	Papilloma diagnosed on core biopsies has a low upgrade rate. Clinical Imaging, 2020, 60, 67-74.	1.5	16
31	High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer toÂaÂNovel Nonanthracycline Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2015, 15, 31-36.	2.4	15
32	Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution. Breast Cancer Research and Treatment, 2021, 185, 573-581.	2.5	15
33	African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Research and Treatment, 2017, 166, 743-755.	2.5	14
34	Magee Equationsâ"¢ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. Modern Pathology, 2021, 34, 77-84.	5.5	14
35	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. Clinical Breast Cancer, 2021, 21, 509-520.	2.4	13
36	Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. PLoS ONE, 2021, 16, e0254125.	2.5	12

Xiaoxian Li

#	Article	IF	CITATIONS
37	Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Breast Cancer Research and Treatment, 2020, 183, 599-606.	2.5	11
38	Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases. Breast Journal, 2018, 24, 889-893.	1.0	10
39	Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Cell Reports Methods, 2021, 1, 100050.	2.9	10
40	Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. PLoS ONE, 2017, 12, e0170095.	2.5	10
41	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	7.0	10
42	HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology Research and Practice, 2020, 216, 153155.	2.3	9
43	Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. International Journal of Clinical and Experimental Pathology, 2014, 7, 2551-7.	0.5	9
44	Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score. Frontiers in Medicine, 0, 9, .	2.6	8
45	Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high-risk breast lesion conferences in an academic center. Breast Cancer Research and Treatment, 2020, 183, 577-584.	2.5	7
46	Nuclear HSET as a negative prognostic indicator and racial disparity biomarker in breast cancer patients Journal of Clinical Oncology, 2015, 33, 1078-1078.	1.6	6
47	Targeted drugs and diagnostic assays Companions in the race to combat ethnic disparity. Frontiers in Bioscience - Landmark, 2017, 22, 193-211.	3.0	5
48	Evaluation of Prognosis in Hormone Receptor–Positive/HER2-Negative and Lymph Node–Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clinical Breast Cancer, 2018, 18, 347-352.	2.4	5
49	The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers. American Journal of Clinical Pathology, 2019, 151, 504-510.	0.7	5
50	Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results Journal of Clinical Oncology, 2018, 36, 1035-1035.	1.6	5
51	Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell Death and Disease, 2022, 13, .	6.3	5
52	Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. Breast Cancer Research and Treatment, 2022, 192, 509-516.	2.5	4
53	Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. Cancers, 2022, 14, 2467.	3.7	4
54	Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas. American Journal of Clinical Pathology, 2018, 150, 491-498.	0.7	3

XIAOXIAN LI

#	Article	IF	CITATIONS
55	Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival Journal of Clinical Oncology, 2017, 35, 1090-1090.	1.6	3
56	Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, 188-196.	2.4	2
57	Updates on Lobular Neoplasms, Papillary, Adenomyoepithelial, and Fibroepithelial Lesions of the Breast. Archives of Pathology and Laboratory Medicine, 2021, , .	2.5	2
58	The Incidence of Occult Malignant and High-Risk Pathologic Findings in Breast Reduction Specimens. Plastic and Reconstructive Surgery, 2021, 148, 534e-539e.	1.4	2
59	The clinical significance of metastatic breast carcinoma to intramammary lymph node. Breast Journal, 2020, 26, 197-205.	1.0	1
60	Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas. Human Pathology, 2021, 116, 73-81.	2.0	1
61	Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study) Journal of Clinical Oncology, 2018, 36, 581-581.	1.6	1
62	Rampant centrosome amplification and aggressive disease course of triple-negative breast cancers Journal of Clinical Oncology, 2015, 33, 1075-1075.	1.6	1
63	A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers Journal of Clinical Oncology, 2016, 34, 1089-1089.	1.6	1
64	Invasive Ductal Carcinoma (NOS) of theÂBreast. , 2019, , 25-37.		0
65	Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer Journal of Clinical Oncology, 2014, 32, 576-576.	1.6	0
66	A novel metric to quantify cell-cycling kinetics and refine the Nottingham Grading System to improve breast cancer patient stratification Journal of Clinical Oncology, 2015, 33, e22149-e22149.	1.6	0
67	A novel prognostic index to improve patient stratification compared to the Nottingham grading system Journal of Clinical Oncology, 2015, 33, e22170-e22170.	1.6	0
68	Consequences of passages: Mitotic indices and centrosome amplification levels variance between patients' tumors and cancer cells cultured in vitro Journal of Clinical Oncology, 2015, 33, e13518-e13518.	1.6	0
69	Sorting the mixed bag: Tumor grade reassignment of Nottingham Grade II patients using pattern classification techniques Journal of Clinical Oncology, 2015, 33, e22165-e22165.	1.6	0
70	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics Journal of Clinical Oncology, 2016, 34, 1091-1091.	1.6	0
71	A combined HER3-EGFR score in triple-negative breast cancer: racial differences Journal of Clinical Oncology, 2016, 34, e12560-e12560.	1.6	0
72	HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer Journal of Clinical Oncology, 2017, 35, 11612-11612.	1.6	0

XIAOXIAN LI

#	Article	IF	CITATIONS
73	Abstract P4-07-31: Racial disparities in breast cancer chiefly reside in the lesser-known quadruple-negative breast cancer. Cancer Research, 2022, 82, P4-07-31-P4-07-31.	0.9	о
74	The impact of obesity on triple negative breast cancer (TNBC) outcomes at a diverse academic cancer center Journal of Clinical Oncology, 2022, 40, e12529-e12529.	1.6	0
75	Impact of race on treatment outcomes in triple-negative breast cancer at an academic medical center Journal of Clinical Oncology, 2022, 40, e12616-e12616.	1.6	0